These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Enoxaparin for primary thromboprophylaxis in ambulatory patients with coronavirus disease-2019 (the OVID study): a structured summary of a study protocol for a randomized controlled trial. Barco S; Bingisser R; Colucci G; Frenk A; Gerber B; Held U; Mach F; Mazzolai L; Righini M; Rosemann T; Sebastian T; Spescha R; Stortecky S; Windecker S; Kucher N Trials; 2020 Sep; 21(1):770. PubMed ID: 32907635 [TBL] [Abstract][Full Text] [Related]
23. Effect of intermediate/high versus low dose heparin on the thromboembolic and hemorrhagic risk of unvaccinated COVID-19 patients in the emergency department. Marchioni C; Esposito G; Calci M; Bais B; Colussi G BMC Emerg Med; 2022 Jun; 22(1):107. PubMed ID: 35698054 [TBL] [Abstract][Full Text] [Related]
24. Risk of major bleeding in patients with venous thromboembolism treated with rivaroxaban or with heparin and vitamin K antagonists. Di Nisio M; Ageno W; Rutjes AW; Pap AF; Büller HR Thromb Haemost; 2016 Jan; 115(2):424-32. PubMed ID: 26511068 [TBL] [Abstract][Full Text] [Related]
25. Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial. Spyropoulos AC; Goldin M; Giannis D; Diab W; Wang J; Khanijo S; Mignatti A; Gianos E; Cohen M; Sharifova G; Lund JM; Tafur A; Lewis PA; Cohoon KP; Rahman H; Sison CP; Lesser ML; Ochani K; Agrawal N; Hsia J; Anderson VE; Bonaca M; Halperin JL; Weitz JI; JAMA Intern Med; 2021 Dec; 181(12):1612-1620. PubMed ID: 34617959 [TBL] [Abstract][Full Text] [Related]
26. Multisite spontaneous hematomas and bleeding in critically ill Chinese patients with COVID-19: two case reports and a literature review. Sha S; Qi S; Qindong S BMC Infect Dis; 2024 Jan; 24(1):101. PubMed ID: 38238658 [TBL] [Abstract][Full Text] [Related]
27. The hazard of fondaparinux in non-critically ill patients with COVID-19: Retrospective controlled study versus enoxaparin. Prandoni P; Cattelan AM; Carrozzi L; Leone L; Filippi L; De Gaudenzi E; Villalta S; Pesavento R; Thromb Res; 2020 Dec; 196():395-397. PubMed ID: 33007739 [No Abstract] [Full Text] [Related]
28. Venous thromboembolism prophylaxis in hospitalized patients: a clinical practice guideline from the American College of Physicians. Qaseem A; Chou R; Humphrey LL; Starkey M; Shekelle P; Ann Intern Med; 2011 Nov; 155(9):625-32. PubMed ID: 22041951 [TBL] [Abstract][Full Text] [Related]
29. Venous Thromboembolism and Heparin Use in COVID-19 Patients: Juggling between Pragmatic Choices, Suggestions of Medical Societies and the Lack of Guidelines. Porfidia A; Pola R J Thromb Thrombolysis; 2020 Jul; 50(1):68-71. PubMed ID: 32367471 [No Abstract] [Full Text] [Related]
31. Thromboelastography-Guided Management of Anticoagulated COVID-19 Patients to Prevent Hemorrhage. Stillson JE; Bunch CM; Gillespie L; Khan R; Wierman M; Pulvirenti J; Phyu H; Anderson S; Al-Fadhl M; Thomas AV; Kwaan HC; Moore E; Moore H; Walsh MM Semin Thromb Hemost; 2021 Jun; 47(4):442-446. PubMed ID: 33607668 [No Abstract] [Full Text] [Related]
32. COVID-19 associated coagulopathy: Thrombosis, hemorrhage and mortality rates with an escalated-dose thromboprophylaxis strategy. Daughety MM; Morgan A; Frost E; Kao C; Hwang J; Tobin R; Patel B; Fuller M; Welsby I; Ortel TL Thromb Res; 2020 Dec; 196():483-485. PubMed ID: 33091700 [TBL] [Abstract][Full Text] [Related]
33. Spontaneous psoas haematoma: a life-threatening complication of anticoagulation in COVID-19. A case series of four episodes. Zerbato V; Bozzato AM; Di Bella S; Giuffrè M; Martingano P; Di Giusto A; Battisti S; Cova MA; Luzzati R; Cavallaro MFM Infect Dis (Lond); 2021 Sep; 53(9):724-729. PubMed ID: 33939587 [TBL] [Abstract][Full Text] [Related]
34. Different Anticoagulant Regimens, Mortality, and Bleeding in Hospitalized Patients with COVID-19: A Systematic Review and an Updated Meta-Analysis. Parisi R; Costanzo S; Di Castelnuovo A; de Gaetano G; Donati MB; Iacoviello L Semin Thromb Hemost; 2021 Jun; 47(4):372-391. PubMed ID: 33851386 [TBL] [Abstract][Full Text] [Related]
35. [Recommendations for the use of thromboprophylaxis in hospitalized patients with COVID-19 in Argentina]. Vazquez FJ; Korin J; Baldessari EM; Capparelli FJ; Gutierrez P; Pale C; Bocanegra F; Grand B; Penchasky D; Gonzalez Alcántara MM; Prémoli MS; Tabares A; Wainsztein N; Odetto D; Vaccaro C; Martínez Aquino E; Cumpian O; Falabella V; Antuel García S; Saadi J; Siccardi M; Gándara E Medicina (B Aires); 2020; 80 Suppl 3():65-66. PubMed ID: 32658849 [TBL] [Abstract][Full Text] [Related]
36. Venovenous Extracorporeal Membrane Oxygenation With Prophylactic Subcutaneous Anticoagulation Only: An Observational Study in More Than 60 Patients. Krueger K; Schmutz A; Zieger B; Kalbhenn J Artif Organs; 2017 Feb; 41(2):186-192. PubMed ID: 27256966 [TBL] [Abstract][Full Text] [Related]
37. Thromboelastography-Guided Anticoagulant Therapy for the Double Hazard of Thrombohemorrhagic Events in COVID-19: A Report of 3 Cases. Bunch CM; Thomas AV; Stillson JE; Gillespie L; Lin KP; Speybroeck J; Kwaan HC; Fulkerson DH; Zamlut M; Khan R; Walsh MM Am J Case Rep; 2021 Apr; 22():e931080. PubMed ID: 33883541 [TBL] [Abstract][Full Text] [Related]
38. Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the INSPIRATION/INSPIRATION-S studies. Bikdeli B; Talasaz AH; Rashidi F; Sharif-Kashani B; Farrokhpour M; Bakhshandeh H; Sezavar H; Dabbagh A; Beigmohammadi MT; Payandemehr P; Yadollahzadeh M; Riahi T; Khalili H; Jamalkhani S; Rezaeifar P; Abedini A; Lookzadeh S; Shahmirzaei S; Tahamtan O; Matin S; Amin A; Parhizgar SE; Jimenez D; Gupta A; Madhavan MV; Parikh SA; Monreal M; Hadavand N; Hajighasemi A; Maleki M; Sadeghian S; Mohebbi B; Piazza G; Kirtane AJ; Lip GYH; Krumholz HM; Goldhaber SZ; Sadeghipour P Thromb Res; 2020 Dec; 196():382-394. PubMed ID: 32992075 [TBL] [Abstract][Full Text] [Related]
39. Cov-hep study: heparin in standard anticoagulation based on citrate for continuous veno-venous hemodialysis in patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial. Lins PRG; de Albuquerque CCC; Assis CF; Rodrigues BCD; E Siqueira Campos BP; de Oliveira Valle E; Cabrera CPS; de Oliveira Gois J; Segura GC; Strufaldi FL; Mainardes LC; Ribeiro RG; Via Reque Cortes DDP; Lutf LG; de Oliveira MFA; Sales GTM; Smolentzov I; Reichert BV; Andrade L; Seabra VF; Rodrigues CE Trials; 2020 Nov; 21(1):920. PubMed ID: 33176886 [TBL] [Abstract][Full Text] [Related]
40. Heparin and SARS-CoV-2: Multiple Pathophysiological Links. Di Micco P; Imbalzano E; Russo V; Attena E; Mandaliti V; Orlando L; Lombardi M; Di Micco G; Camporese G; Annunziata S; Piccinocchi G; Pacelli W; Del Guercio M Viruses; 2021 Dec; 13(12):. PubMed ID: 34960754 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]